Dermata Therapeutics Warrant Stock Analysis
| DRMAW Stock | USD 0.01 0.00 0.00% |
Dermata Therapeutics Warrant is overvalued with Real Value of 0.008085 and Hype Value of 0.01. The main objective of Dermata Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what Dermata Therapeutics Warrant is worth, separate from its market price. There are two main types of Dermata Therapeutics' stock analysis: fundamental analysis and technical analysis.
The Dermata Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Dermata Therapeutics is usually not traded on Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day. Dermata Stock trading window is adjusted to America/New York timezone.
Dermata |
Dermata Stock Analysis Notes
The company recorded a loss per share of 2.16. Dermata Therapeutics had not issued any dividends in recent years. To learn more about Dermata Therapeutics Warrant call the company at 858 800 2543 or check out https://www.dermatarx.com.Dermata Therapeutics Investment Alerts
| Dermata Therapeutics is not yet fully synchronised with the market data | |
| Dermata Therapeutics is way too risky over 90 days horizon | |
| Dermata Therapeutics has some characteristics of a very speculative penny stock | |
| Dermata Therapeutics appears to be risky and price may revert if volatility continues | |
| Dermata Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (7.79 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Dermata Therapeutics generates negative cash flow from operations | |
| Dermata Therapeutics has a frail financial position based on the latest SEC disclosures |
Dermata Profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.98) | (1.03) | |
| Return On Capital Employed | (1.27) | (1.33) | |
| Return On Assets | (0.98) | (1.03) | |
| Return On Equity | (1.23) | (1.29) |
Management Efficiency
The company has return on total asset (ROA) of (0.9068) % which means that it has lost $0.9068 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.7301) %, meaning that it generated substantial loss on money invested by shareholders. Dermata Therapeutics' management efficiency ratios could be used to measure how well Dermata Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.03 in 2024. Return On Capital Employed is likely to drop to -1.33 in 2024. Debt To Assets is likely to climb to 5.53 in 2024, whereas Total Assets are likely to drop slightly above 6.4 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 32.76 | 34.40 | |
| Tangible Book Value Per Share | 32.76 | 34.40 | |
| Enterprise Value Over EBITDA | (20.62) | (21.65) | |
| Price Book Value Ratio | 0.28 | 0.29 | |
| Enterprise Value Multiple | (20.62) | (21.65) | |
| Price Fair Value | 0.28 | 0.29 | |
| Enterprise Value | 70.8 M | 67.2 M |
Evaluating the management effectiveness of Dermata Therapeutics allows investors to assess its financial health and operational efficiency. Coupled with an analysis of its growth prospects and the current market dynamics, we evaluate the stock's true value and future potential. Key indicators such as revenue, earnings or debt levels are examined alongside external factors like economic trends and regulatory changes. The Dermata Stock analysis seeks to determine whether the stock is undervalued, appropriately priced, or overvalued, thereby guiding your investment decisions.
Beta 0.792 | Return On Assets (0.91) | Return On Equity (1.73) |
Dermata Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Dermata Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Dermata Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Dermata Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
David Hale over six months ago Acquisition by David Hale of 10000 shares of Dermata Therapeutics at 0.6099 subject to Rule 16b-3 | ||
Fisher Mary over six months ago Acquisition by Fisher Mary of 5000 shares of Dermata Therapeutics at 1.88 subject to Rule 16b-3 | ||
Sandler Andrew Seth over six months ago Acquisition by Sandler Andrew Seth of 10000 shares of Dermata Therapeutics at 0.6099 subject to Rule 16b-3 | ||
Bedoya-toro Munera Maria E over six months ago Acquisition by Bedoya-toro Munera Maria E of 15000 shares of Dermata Therapeutics at 1.88 subject to Rule 16b-3 |
Dermata Therapeutics Predictive Daily Indicators
Dermata Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Dermata Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Rate Of Daily Change | 1.0 | |||
| Day Median Price | 0.0088 | |||
| Day Typical Price | 0.0088 | |||
| Relative Strength Index | 49.0 |
About Dermata Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Dermata Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Dermata shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Dermata Therapeutics. By using and applying Dermata Stock analysis, traders can create a robust methodology for identifying Dermata entry and exit points for their positions.
| Last Reported | Projected for Next Year |
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Dermata Therapeutics to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Competition Analyzer Now
Competition AnalyzerAnalyze and compare many basic indicators for a group of related or unrelated entities |
| All Next | Launch Module |
Additional Tools for Dermata Stock Analysis
When running Dermata Therapeutics' price analysis, check to measure Dermata Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dermata Therapeutics is operating at the current time. Most of Dermata Therapeutics' value examination focuses on studying past and present price action to predict the probability of Dermata Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dermata Therapeutics' price. Additionally, you may evaluate how the addition of Dermata Therapeutics to your portfolios can decrease your overall portfolio volatility.